

Edgar Filing: ORPHAN MEDICAL INC - Form 8-K

ORPHAN MEDICAL INC
Form 8-K
October 31, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2003

ORPHAN MEDICAL, INC.

(Exact name of registrant as specified in its charter)

| | | |
|--|---|---|
| Delaware ----- (State or other jurisdiction of incorporation) | 0-24760 ----- (Commission file number) | 41-1784594 ----- (I.R.S. employer identification number) |
| Suite 250, 13911 Ridgedale Drive, Minnetonka, MN ----- (Address of principal executive offices) | 55305 ----- (zip code) | (952) 513-6900 ----- (Registrant's telephone number, including area code) |

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events.

The Company announced a licensing agreement with Celltech Pharmaceuticals, a division of Celltech Group plc, for the sales and marketing rights for Xyrem(R) (sodium oxybate) oral solution in Europe. The Company received \$2.5 million of initial proceeds from the transaction. This agreement was discussed in the Company's press release dated October 30, 2003. The press release is attached as Exhibit 99.1 to this Form 8-K.

Item 7. Financial Statements and Exhibits

Edgar Filing: ORPHAN MEDICAL INC - Form 8-K

Exhibit 99.1 - Press release dated October 30, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 31, 2003

ORPHAN MEDICAL, INC.

/s/ Timothy G. McGrath

Timothy G. McGrath
Chief Financial Officer
(duly authorized officer and
principal financial officer)

EXHIBIT INDEX

| Exhibit Number | Description |
|-------------------|---------------------------------------|
| 99.1 | Press release dated October 30, 2003. |